<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03064568</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20150554H</org_study_id>
    <nct_id>NCT03064568</nct_id>
  </id_info>
  <brief_title>Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy</brief_title>
  <official_title>Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose is to identify if misoprostol in addition to local vasopressin decreases blood loss&#xD;
      when compared to vasopressin alone, which is our current practice at this time. The study&#xD;
      will be double-blinded with neither the patient nor the researcher knowing whether the&#xD;
      placebo or the misoprostol was given. We will monitor patients for decrease in hemoglobin and&#xD;
      hematocrit, need for transfusion, and operative time among other measures of perioperative&#xD;
      morbidity to see if the addition of misoprostol makes a significant difference. We will also&#xD;
      observe patients to see if there are any side effects of misoprostol that make its use&#xD;
      undesirable.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All women with planned myomectomy receive Depo Leupron prior to surgery per standard care and&#xD;
      undergo routine pre-operative laboratory testing including hemoglobin and hematocrit. If&#xD;
      enrolled in the study, patients will be consented at their pre-op appointment for the study&#xD;
      and be asked to complete a visual analog scale to assess pre-operative pain. Patients will be&#xD;
      randomized to receive misoprostol 800mcg per rectum or an identical inert tablet(s) per&#xD;
      rectum 30 minutes preoperatively. Randomization will be performed by a third party so that&#xD;
      neither the surgeon nor patient will know which intervention was performed, and interventions&#xD;
      will be placed in sealed, sequentially numbered, opaque envelopes. Researcher team will have&#xD;
      all needed data corresponding with randomized code which will be broken at conclusion of&#xD;
      study and will be able to match code with patient's initials and medical record number after&#xD;
      study completion to analyze data. Myomectomy will then be performed per standard care with&#xD;
      the use of local vasopressin to aid in decreasing blood loss per our normal standard of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2016</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective double-blinded study completed at a tertiary care center</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Randomization to treatment arm done by 3rd party. Randomization will be performed by a third party so that neither the surgeon nor patient will know which intervention was performed, and interventions will be placed in sealed, sequentially numbered, opaque envelopes. The code will only be broken at time of data analysis once all patients have been enrolled.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical blood loss</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Estimated blood loss during surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Febrile morbiditiy</measure>
    <time_frame>24 hours postop</time_frame>
    <description>Evidence of fever or infection postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for blood transfusion</measure>
    <time_frame>intraoperative to 24 hours postoperative</time_frame>
    <description>Patient requirement of blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>24 hours postop</time_frame>
    <description>Assessment of patient subjective pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication side-effects</measure>
    <time_frame>24 hours postop</time_frame>
    <description>Surveillance for any adverse side effects from misoprostol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myomectomy; Surgical Blood Loss</condition>
  <arm_group>
    <arm_group_label>Misoprostol 100Mcg Tab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive misoprostol 400mcg per rectum 30 minutes preoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive identical inert tablets per rectum 30 minutes preoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol 100Mcg Tab</intervention_name>
    <arm_group_label>Misoprostol 100Mcg Tab</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female age 20-50 y/o who plan to undergo abdominal myomectomy for symptomatic&#xD;
             myomatous uterus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with contraindication to misoprostol or vasopressin, personal history or&#xD;
             cardiac or pulmonary disease, history of prior myomectomy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patient must have a uterus to participate</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randal M Robinson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Health San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Randal M Robinson, MD</last_name>
    <phone>210-567-4950</phone>
    <email>robinsonr3@uthscsa.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Lukes Baptist Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randal Robinson, MD</last_name>
      <phone>210-567-4950</phone>
      <email>robinsonr3@uthscsa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randal Robinson, MD</last_name>
      <phone>210-567-4950</phone>
      <email>robinsonr3@uthscsa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randal Robinson, MD</last_name>
      <phone>210-567-4950</phone>
      <email>robinsonr3@uthscsa.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 22, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2017</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myomectomy, Misoprostol, Vasopressin, Blood loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

